Rafferty Asset Management’s Pacira BioSciences PCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-10,092
| Closed | -$251K | – | 1097 |
|
|
2025
Q1 | $251K | Buy |
+10,092
| New | +$251K | ﹤0.01% | 998 |
|
|
2024
Q4 | – | Sell |
-14,847
| Closed | -$223K | – | 1167 |
|
|
2024
Q3 | $223K | Buy |
14,847
+7,423
| +100% | +$112K | ﹤0.01% | 1087 |
|
|
2024
Q2 | $212K | Buy |
+7,424
| New | +$212K | ﹤0.01% | 1122 |
|
|
2024
Q1 | – | Sell |
-6,217
| Closed | -$210K | – | 1092 |
|
|
2023
Q4 | $210K | Buy |
+6,217
| New | +$210K | ﹤0.01% | 1058 |
|
|
2022
Q4 | – | Sell |
-4,404
| Closed | -$234K | – | 1145 |
|
|
2022
Q3 | $234K | Buy |
4,404
+154
| +4% | +$8.18K | ﹤0.01% | 1064 |
|
|
2022
Q2 | $248K | Buy |
4,250
+5
| +0.1% | +$292 | ﹤0.01% | 990 |
|
|
2022
Q1 | $324K | Sell |
4,245
-3,209
| -43% | -$245K | ﹤0.01% | 1091 |
|
|
2021
Q4 | $449K | Buy |
7,454
+312
| +4% | +$18.8K | ﹤0.01% | 1082 |
|
|
2021
Q3 | $400K | Buy |
7,142
+1,735
| +32% | +$97.2K | ﹤0.01% | 1095 |
|
|
2021
Q2 | $328K | Buy |
5,407
+867
| +19% | +$52.6K | ﹤0.01% | 1157 |
|
|
2021
Q1 | $318K | Sell |
4,540
-1,812
| -29% | -$127K | ﹤0.01% | 1066 |
|
|
2020
Q4 | $380K | Buy |
6,352
+1,133
| +22% | +$67.8K | ﹤0.01% | 751 |
|
|
2020
Q3 | $314K | Buy |
5,219
+642
| +14% | +$38.6K | ﹤0.01% | 798 |
|
|
2020
Q2 | $240K | Buy |
+4,577
| New | +$240K | ﹤0.01% | 878 |
|
|
2020
Q1 | – | Sell |
-4,908
| Closed | -$222K | – | 752 |
|
|
2019
Q4 | $222K | Sell |
4,908
-3,794
| -44% | -$172K | ﹤0.01% | 827 |
|
|
2019
Q3 | $331K | Buy |
8,702
+2,951
| +51% | +$112K | 0.01% | 736 |
|
|
2019
Q2 | $250K | Buy |
+5,751
| New | +$250K | ﹤0.01% | 761 |
|
|
2015
Q1 | – | Sell |
-5,331
| Closed | -$473K | – | 579 |
|
|
2014
Q4 | $473K | Buy |
+5,331
| New | +$473K | 0.11% | 241 |
|